# 4D Molecular Therapeutics, Inc.: overview FDMT · Nasdaq · CIK 1650648 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fdmt.md) · [Financials](/companies/fdmt/financials.md) · [Filings](/companies/fdmt/filings.md) · [Insiders](/companies/fdmt/insiders.md) Latest reported revenue: [$3.8m](/filings/0001193125-26-349173.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-349173). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001193125-25-273343.md) | [0.0 d](/filings/0001193125-26-114075.md) | [0.0](/filings/0001193125-26-211939.md) | [0.0](/filings/0001193125-26-349173.md) | [0.1](/filings/0001193125-25-273343.md) | [85.1 d](/filings/0001193125-26-114075.md) | [3.0](/filings/0001193125-26-211939.md) | [3.8](/filings/0001193125-26-349173.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1704400.0%)](/filings/0001193125-25-273343.md) | [(5611700.0%) d](/filings/0001193125-26-114075.md) | [(383007.1%)](/filings/0001193125-26-211939.md) | [(396373.3%)](/filings/0001193125-26-349173.md) | [(67983.3%)](/filings/0001193125-25-273343.md) | [17.3% d](/filings/0001193125-26-114075.md) | [(2416.1%)](/filings/0001193125-26-211939.md) | [(2037.2%)](/filings/0001193125-26-349173.md) | | Net margin | % | [(1461433.3%)](/filings/0001193125-25-273343.md) | [(4967100.0%) d](/filings/0001193125-26-114075.md) | [(342657.1%)](/filings/0001193125-26-349173.md) | [(364386.7%)](/filings/0001193125-26-349173.md) | [(63195.6%)](/filings/0001193125-25-273343.md) | [22.8% d](/filings/0001193125-26-114075.md) | [(2256.6%)](/filings/0001193125-26-349173.md) | [(1929.0%)](/filings/0001193125-26-349173.md) | | Diluted EPS | $ per share | [(0.79)](/filings/0001193125-25-273343.md) | not reported | [(0.86)](/filings/0001193125-26-211939.md) | [(0.98)](/filings/0001193125-26-349173.md) | [(1.01)](/filings/0001193125-25-273343.md) | not reported | [(1.01)](/filings/0001193125-26-211939.md) | [(1.04)](/filings/0001193125-26-349173.md) | | Free cash flow | $m | [(31.2) d](/filings/0001193125-25-273343.md) | [(46.8) d](/filings/0001193125-26-114075.md) | [(48.4)](/filings/0001193125-26-211939.md) | [(43.4) d](/filings/0001193125-26-349173.md) | [(46.6) d](/filings/0001193125-25-273343.md) | [28.5 d](/filings/0001193125-26-114075.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.0](/filings/0000950170-23-008142.md) | [3.1](/filings/0000950170-24-023183.md) | [20.7](/filings/0000950170-25-030056.md) | [0.0](/filings/0001193125-26-114075.md) | [85.2](/filings/0001193125-26-114075.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(395.5%)](/filings/0000950170-23-008142.md) | [(3516.5%)](/filings/0000950170-24-023183.md) | [(544.6%)](/filings/0000950170-25-030056.md) | [(507678.4%)](/filings/0001193125-26-114075.md) | [(187.2%)](/filings/0001193125-26-114075.md) | | Net margin | % | [(395.4%)](/filings/0000950170-23-008142.md) | [(3435.4%)](/filings/0000950170-24-023183.md) | [(486.6%)](/filings/0000950170-25-030056.md) | [(434778.4%)](/filings/0001193125-26-114075.md) | [(164.4%)](/filings/0001193125-26-114075.md) | | Diluted EPS | $ per share | [(2.57)](/filings/0000950170-23-008142.md) | [(3.32)](/filings/0000950170-24-023183.md) | [(2.58)](/filings/0000950170-25-030056.md) | [(2.98)](/filings/0001193125-26-114075.md) | [(2.42)](/filings/0001193125-26-114075.md) | | Free cash flow | $m | [(78.2)](/filings/0000950170-23-008142.md) | [(98.2)](/filings/0000950170-24-023183.md) | [(78.6)](/filings/0000950170-25-030056.md) | [(138)](/filings/0001193125-26-114075.md) | [(110)](/filings/0001193125-26-114075.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fdmt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $76.5m | 5,746,289 | | Not compared | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $67.2m | 5,049,779 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $60.5m | 4,546,059 | | Added +400,756 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $56.6m | 4,258,668 | | Added +53,230 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $48.9m | 5,247,151 | | Not compared | | [NOVO HOLDINGS A/S](/funds/1388325.md) | 2026-06-30 | $43.2m | 3,249,178 | | Reduced −401,559 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $38.7m | 2,911,109 | | Added +203,234 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $38.3m | 2,879,289 | | Unchanged | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $29.9m | 2,249,203 | | Added +644,047 | | [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $29.6m | 2,227,917 | | Added +925,000 | ## Recent filings [All 428 filings](/companies/fdmt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 12:05 ET | [8-K](/filings/0001193125-26-403424.md) | 8.01 Other events | 0001193125-26-403424 | | 2026-08-13 | 20:09 ET | [10-Q](/filings/0001193125-26-349173.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349173 | | 2026-08-13 | 20:06 ET | [8-K](/filings/0001193125-26-349160.md) | 2.02 Results of operations | 0001193125-26-349160 | | 2026-07-20 | 12:30 ET | [8-K](/filings/0001193125-26-308409.md) | 8.01 Other events | 0001193125-26-308409 | | 2026-06-29 | 12:05 ET | [8-K](/filings/0001193125-26-286880.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-26-286880 | | 2026-06-22 | 20:21 ET | [8-K](/filings/0001193125-26-277563.md) | 5.07 Shareholder vote results | 0001193125-26-277563 | | 2026-05-07 | 20:13 ET | [10-Q](/filings/0001193125-26-211939.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211939 | | 2026-05-07 | 20:10 ET | [8-K](/filings/0001193125-26-211904.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211904 | | 2026-04-28 | 20:05 ET | [DEF 14A](/filings/0001140361-26-017427.md) | Proxy statement, period 2026-06-17 | 0001140361-26-017427 | | 2026-03-30 | 21:29 ET | [8-K](/filings/0001193125-26-131739.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-131739 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-114075.md), filed Mar 18, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/05cb3fcc-01f0-44ba-9517-44c4da9fae23) ## About the filer - CIK: 1650648 - Tickers: FDMT - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.